File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

TitleIn vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Authors
KeywordsAntiviral compounds
Epidemics
Severe acute respiratory syndrome
Issue Date2004
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcv
Citation
Journal of Clinical Virology, 2004, v. 31 n. 1, p. 69-75 How to Cite?
AbstractEffective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics. © 2004 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163121
ISSN
2015 Impact Factor: 2.647
2015 SCImago Journal Rankings: 1.503
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChen, SFen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorJiang, Yen_HK
dc.contributor.authorKao, RYTen_HK
dc.contributor.authorLu, HTen_HK
dc.contributor.authorFan, KWen_HK
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorTsui, WHWen_HK
dc.contributor.authorHung, IFNen_HK
dc.contributor.authorLee, TSWen_HK
dc.contributor.authorGuan, Yen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2012-09-05T05:27:53Z-
dc.date.available2012-09-05T05:27:53Z-
dc.date.issued2004en_HK
dc.identifier.citationJournal of Clinical Virology, 2004, v. 31 n. 1, p. 69-75en_HK
dc.identifier.issn1386-6532en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163121-
dc.description.abstractEffective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics. © 2004 Elsevier B.V. All rights reserved.en_HK
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcven_HK
dc.relation.ispartofJournal of Clinical Virologyen_HK
dc.rightsJournal of Clinical Virology. Copyright © Elsevier BV.-
dc.subjectAntiviral compoundsen_HK
dc.subjectEpidemicsen_HK
dc.subjectSevere acute respiratory syndromeen_HK
dc.subject.meshAdulten_US
dc.subject.meshAntiviral Agents - Pharmacologyen_US
dc.subject.meshCell Lineen_US
dc.subject.meshChlorogenic Acid - Chemistry - Pharmacologyen_US
dc.subject.meshDrug Synergismen_US
dc.subject.meshFemaleen_US
dc.subject.meshFlavonoids - Chemistry - Pharmacologyen_US
dc.subject.meshGlycyrrhizic Acid - Chemistry - Pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Pharmacologyen_US
dc.subject.meshInterferon-Beta - Pharmacologyen_US
dc.subject.meshLopinaviren_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPyrimidinones - Pharmacologyen_US
dc.subject.meshRibavirin - Pharmacologyen_US
dc.subject.meshRimantadine - Pharmacologyen_US
dc.subject.meshSars Virus - Drug Effectsen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Virologyen_US
dc.subject.meshViral Plaque Assayen_US
dc.titleIn vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsen_HK
dc.typeArticleen_HK
dc.identifier.emailChen, SF: sfchen@hku.hken_HK
dc.identifier.emailKao, RYT: rytkao@hkucc.hku.hken_HK
dc.identifier.emailFan, KW: keithfan@hkucc.hku.hken_HK
dc.identifier.emailCheng, VCC: vcccheng@HKUCC.hku.hken_HK
dc.identifier.emailTsui, WHW: wayne@hkucc.hku.hken_HK
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_HK
dc.identifier.emailGuan, Y: yguan@hkucc.hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityChen, F=rp00672en_HK
dc.identifier.authorityKao, RYT=rp00481en_HK
dc.identifier.authorityHung, IFN=rp00508en_HK
dc.identifier.authorityGuan, Y=rp00397en_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jcv.2004.03.003en_HK
dc.identifier.pmid15288617-
dc.identifier.scopuseid_2-s2.0-3543143713en_HK
dc.identifier.hkuros106299-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-3543143713&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume31en_HK
dc.identifier.issue1en_HK
dc.identifier.spage69en_HK
dc.identifier.epage75en_HK
dc.identifier.isiWOS:000223456200013-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridChen, F=7404907980en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridJiang, Y=24605346600en_HK
dc.identifier.scopusauthoridKao, RYT=7101675499en_HK
dc.identifier.scopusauthoridLu, HT=55186375200en_HK
dc.identifier.scopusauthoridFan, KW=7202978325en_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridTsui, WHW=36124344600en_HK
dc.identifier.scopusauthoridHung, IFN=7006103457en_HK
dc.identifier.scopusauthoridLee, TSW=7501439333en_HK
dc.identifier.scopusauthoridGuan, Y=7202924055en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.customcontrol.immutablesml 130524-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats